Galapagos (GLPG) stock dips as Morgan Stanley downgrades its rating to Underweight from Equal Weight amid its CAR-T therapy ...

In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Fintel reports that on February 14, 2025, Morgan Stanley downgraded their outlook for Galapagos NV - Depositary Receipt () ...

In a report released on February 13, Christophe dombu from Kepler Capital maintained a Sell rating on Galapagos (0JXZ – Research Report), with ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...

Q4 2024 Management View CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...

In its annual results statement, Galapagos chief financial officer Thad Huston said the firm is moving ahead with a planned ...

Presidents Daniel Noboa of Ecuador and Gustavo Petro of Colombia met Sunday at the Charles Darwin Research Station in the Galapagos Islands to discuss environmental protection initiatives ...

The new National Geographic Delfina is embarking on its maiden voyage for National Geographic-Lindblad Expeditions this weekend. Acquired from Celebrity Cruises in 2024, the 16-guest catamaran became ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...